SABCS 2021

Good data with further questions for future treatment in a neoadjuvant setting

Benefit only related to chemotherapy?!

The next standard for TNBC?!

Negative results with hope for translational projects

The risk-adapted decision for or against AI has to be redefined

Critical consideration of the study data is necessary

Molecular-guided treatment is of value in combination with other therapeutics

Metformin is not an anti-cancer drug

Re-evaluation confirms old data

Metformin shows no efficacy for most cancer patients

Hypothesis-generating study in the HER2-enriched subtype

Genomic signatures of DCIS

Solved and unsolved controversies of early breast cancer

Leading the way for other ct-DNA trials

Muss die risiko-adaptierte Entscheidungsfindung bei AI überdacht werden?

"Signatures Genomiche " nel carcinoma duttale in situ

La metformina non può essere considerata un farmaco antitumorale

Negative Ergebnisse, aber Hoffnung für translationale Projekte

Kritische Betrachtung der Studiendaten notwendig

Erneute Auswertung bestätigt alte Daten

Hypothesen-generierende Studie beim HER2-enriched Subtyp

Genomisch gesteuererte Therapie sinnvoll in Kombi mit weiteren Therapeutika

E’ solo effetto della chemioterapia?

KEYNOTE-522 confirms ICI benefit in the neoadjuvant setting; what about toxicity?

RxPONDER: Benefit only for pre-menopausal patients? OFS/AI > CT? OFS leading to OS benefit?

cTRAK TN: ctDNA monitoring not yet ready for primetime. Lots of questions, very few answers!

HR+ EBC: What about PALLAS/PENELOPE-B? What is the difference to monarchE (Follow Up, Duraction, Administration, the drug itself)? PARPi vs. cdk4/6i?

TNBC EBC: What is the new neoadjuvant standard treatment? The role of TILS, TMB, further predictive markers for ICI (gene expression signatures, CD8 infiltartion pattern, intrinsic subtypes, ctDNA) and PARP (HRD, sBRCA+, gPALB2+)

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of relapse or stratification of post-neoadjuvant treatment, new trials in premenopausal patients, NGS in early disease

HER2+ EBC: Chemotherapy free regimens? Extended adjuvant therapy? T-Dxd? Duuration of trastuzumab? What about HER2 low?

Which patients will benefit from Pembro in metastatic TNBC?

Oral SERDs for early setting and adjuvant therapy

Oral SERDs are efficient, but show high progression rate

Samuraciclib - new targeted therapy for luminal breast cancer?

Elacestrant - less than we expected

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Precision oncology is beneficial in certain mBC patients

PFS improvement with fulvestrant in patients with emerging ESR1 mutation

Chekpoint inhibition in breast cancer

Pooled analyses shows OS benefit for most subgroups

Immuntherapy for high tumor mutation burden in metastatic breast cancer patients

Imaging with mass cytometry can provide predictive information for therapy with immune checkpoint inhibitors

Best of the year: systemic therapy

Switching with molecular progress improves PFS

Effectiveness depending on PDL1 status

TDXd is very efficient in patients with brain metastasis

Promising results for TNBC patients

Robust benefit of pembroluzimab in addition to chemotherapy

Pioneering study of personalized medicine in advanced breast cancer

TROP2 - new target for improved chemotherapy

IO + IO without resounding success in the mBC setting

Final results of the CPS score subgroup analyses show the optimal cutoff for mTNBC

Dato-Dxd for metastatic TNBC

Activity of T-Dxd across all Her2-expressing breast cancers

Dato-DXd new promising ADC

Reconfirming effect of T-DXd in patients with brain metastasis

More good news for TDXd

Very good news for endocrine resistant metastatic patients

My highlights of 2021 in metastatic breast cancer

Amazing period for patients with refractory metastatic TNBC

T-Dxd is also active in patients with brain metastasis

3 updates - 3 new standards of care

Exciting novel therapies for metastatic TNBC

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

È un grande momento per i pazienti con tumore mammario metastatico triplo-negativo

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Samuracyklib – nowe leczenie celowane w rakach luminalnych?

Checkpoint-Inhibition beim Mammakarzinom

Neues Target für optimierte Chemotherapie

Mi retrospectiva del cáncer de mama metastático en 2021

L’imaging mass cytometry può aiutare a predire l’efficacia dell’immunoterapia

Gepoolte Analyse zeigt OS Vorteil für fast alle Subgruppe

Résultats prometteurs dans le cancer du sein triple négatif

Amélioration de la survie sans progression par le switch fulvestrant en cas d’apparition mutation ESR1 sous inhibiteurs aromatase

Elacestrant – poniżej oczekiwań

Dato-DXd – nowy obiecujący koniugat przeciwciała i cytostatyku

Buone notizie per i tumori mammari endocrino resistenti

Umstellung bei molekularem Progress verlängert PFS

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil durch CDK4/6i

Best of the Year: Systemtherapie

Werden orale SERDs die Therapie mit Fulvestrant in Zukunft ablösen?

Important benefice de l’ajout du pembrolizumab à la chimiothérapie

Wegweisende Daten für die personalisierte Medizin beim fortgeschrittenen Mammakarzinom

Resultados finales de los análisis de los subgrupos de puntuación CPS demuestran el umbral ideal para pacientes de cáncer de mama triple negativo metastásico.

T-Dxd aktywny również w przerzutach do mózgu

IO + IO ohne durchschlagenden Erfolg beim mBC

Activité du T-DXd dans les metastases cérébrales

Risultati promettenti nel tumore al seno triplo negativo

Präzisionsonkologie funktioniert beim mBC

MBC HER2+: How can we manage the metastatic disease and how can we improve therapy by de-escalating treatment in the metastatic setting?

MBC TNBC: Molecular tumor characteristics define the efficacy of new treatments - how do we implement new treatments in clinical practice?

MBC HR+: What is the best option after a CDK4/6i therapy?

Integrating patients perspectives in metastatic breast cancer

Therapy of brain metastasis – can T-DXd be the new SoC?

New ADCs on the horizon for TNBC patients

Targeting rare mutations in breast cancer - is this the way to go?

Treatment options for patients with metastatic TNBC

Are SERDs a future therapy for endocrine resistant metastatic patients?!